10-K: Alzamend Neuro Faces Going Concern Doubts Amidst Clinical Trial Delays and Funding Needs

Alzamend Neuro's latest 10-K filing reveals significant financial challenges, including recurring losses and a going concern opinion, alongside a major delay in its ALZN002 Alzheimer's clinical trial, despite progress with its AL001 program.

Summary

• Alzamend Neuro, a clinical-stage biopharmaceutical company, is focused on developing treatments for Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD).
• The company's pipeline includes two drug candidates: AL001, an ionic cocrystal of lithium, and ALZN002, a cell-based therapeutic vaccine.
• AL001 has completed Phase IIA clinical trials, successfully identifying a maximum tolerated dose (MTD) of 240 mg lithium carbonate equivalent, designed to potentially avoid therapeutic drug monitoring (TDM).
• A partnership with Massachusetts General Hospital (MGH) and Harvard Medical School was announced in August 2024 to conduct five Phase II imaging clinical trials for AL001 across multiple indications, with the first trial for healthy subjects initiated in May 2025.
• Preclinical data for AL001 showed higher lithium concentrations in brain tissues at lower doses compared to lithium carbonate, suggesting potential for enhanced safety and efficacy.
• The ALZN002 Phase I/IIA clinical trial for mild to moderate Alzheimer's dementia, initiated in April 2023, has been significantly delayed due to the termination of the contract with its Contract Research Organization (CRO), Biorasi, LLC, with resumption not expected until mid-2026.
• The company reported a net loss of $4.5 million for the fiscal year ended April 30, 2025, compared to $9.9 million for the prior year.
• Research and development expenses decreased significantly to $1.4 million in FY2025 from $6.5 million in FY2024, primarily due to lower professional and clinical trial fees.
• General and administrative expenses decreased to $3.1 million in FY2025 from $3.5 million in FY2024.
• As of April 30, 2025, the company had $3.9 million in cash and cash equivalents and an accumulated deficit of $58.5 million.
• The independent registered public accounting firm issued a going concern opinion, citing insufficient capital to fund operations for the next twelve months.
• The company has identified a material weakness in its internal control over financial reporting related to insufficient accounting personnel and inadequate IT General Controls.
• Alzamend Neuro raised $2.7 million from an At-the-Market (ATM) offering in FY2025, which was terminated in April 2025, and raised $7.7 million from the sale of Series A and Series C Convertible Preferred Stock.
• Subsequent to year-end, the company completed the sale of Series C Convertible Preferred Stock, raising an additional $4.0 million, and converted 575.7176 shares of Series C Preferred Stock into 2,117,699 shares of Common Stock by July 22, 2025.
• The company's common stock was subject to two reverse stock splits: one-for-ten effective July 16, 2024, and one-for-nine effective May 12, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, evidenced by a 'going concern' opinion and recurring losses. A major clinical trial (ALZN002) is severely delayed, impacting future prospects. While AL001 shows some positive preclinical and early clinical progress, the overall financial instability and critical trial setback outweigh these positives, indicating a high-risk investment with substantial uncertainty regarding long-term viability and profitability.

Positives

• AL001 Phase IIA clinical trial successfully identified a maximum tolerated dose (MTD) of 240 mg lithium carbonate equivalent, potentially mitigating the need for therapeutic drug monitoring (TDM).
• Preclinical studies for AL001 demonstrated consistently higher lithium concentrations in brain tissues at lower doses compared to lithium carbonate, suggesting improved brain bioavailability and reduced systemic toxicity.
• Partnership with Massachusetts General Hospital and Harvard Medical School for five Phase II imaging clinical trials for AL001 across multiple indications (Alzheimer's, BD, MDD, PTSD) indicates significant clinical advancement and external validation.
• The first Phase II imaging trial for AL001 in healthy human subjects has been initiated, enrolled, and dosed, with topline data expected by the end of 2025.
• Received 'study may proceed' letters from the FDA for Investigational New Drug (IND) applications for AL001 in BD, MDD, and PTSD, expanding potential indications.
• Net loss decreased by 55% from $9.9 million in FY2024 to $4.5 million in FY2025, and research and development expenses decreased by 78% due to lower clinical trial and professional fees.
• Successfully raised $7.7 million from preferred stock sales and $2.7 million from ATM offerings in FY2025, and an additional $4.0 million post-year end from Series C Preferred Stock sales, demonstrating continued access to capital.

Negatives

• The company has incurred recurring net losses and negative cash flows from operations, leading its independent registered public accounting firm to express substantial doubt about its ability to continue as a going concern.
• The ALZN002 Phase I/IIA clinical trial for Alzheimer's has experienced a significant delay, with resumption not expected until mid-2026, due to the termination of the contract with its Contract Research Organization (CRO), Biorasi, LLC.
• The company currently has no source of near-term revenue and does not anticipate generating revenue for at least the next several years, if ever, and may never achieve profitability.
• A material weakness in internal control over financial reporting was identified, stemming from insufficient accounting personnel and inadequate IT General Controls, which could affect the accuracy and timeliness of financial reporting.
• The company's future capital requirements are substantial and depend on many factors, including the success and costs of clinical trials, regulatory approvals, and manufacturing, with no assurance of obtaining adequate additional financing on acceptable terms.
• The market price of the company's common stock is highly volatile, having fluctuated between $5.94 and $66.15 per share in FY2025, and is subject to factors beyond the company's control.
• The company has effected two reverse stock splits (one-for-ten and one-for-nine) within a year, which can often be perceived negatively by investors and may indicate challenges in maintaining Nasdaq listing requirements or share price.

Risks

• Need to obtain substantial additional funding to complete development and commercialization of AL001 and ALZN002; inability to raise capital may force delays or elimination of R&D programs.
• Early stage of clinical development with no near-term revenue source and may never become profitable.
• Limited operating history on which to judge business prospects and management.
• Operational and financial milestones must be met to maintain licensing rights to technology and intellectual property from the University of South Florida Research Foundation; failure could lead to loss of rights.
• Substantial dependence on the success of product candidates (AL001 and ALZN002), which may not receive regulatory approval or be successfully commercialized.
• Serious adverse events or other safety risks could require abandonment of development, or delay/limit approval or market acceptance of AL001 or ALZN002.
• Development and regulatory approval of drug candidates present numerous risks, including high failure rates in clinical trials, especially for Alzheimer's drugs.
• Failure to attract and retain senior management and key scientific personnel could hinder successful development and commercialization.
• Intellectual property rights present risks, including potential litigation, inability to prevent disclosure of trade secrets, and challenges to patent validity or enforceability.
• Affiliates and related party transactions present potential conflicts of interest due to overlapping management with other entities (e.g., Hyperscale Data, Inc.).
• Failure to comply with Nasdaq Capital Market continued listing requirements could result in delisting, adversely affecting stock price and liquidity.
• Market price volatility of common stock could result in substantial losses for investors.
• Material weakness in internal control over financial reporting; if remediation is ineffective, it could affect accurate and timely financial reporting and investor confidence.
• Potential product liability lawsuits related to testing and commercialization of AL001 or ALZN002 could incur substantial liabilities.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information could enable competitors to duplicate technologies.
• Subject to U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, and sanctions laws; failure to comply could lead to penalties.
• Certain provisions of certificate of incorporation, bylaws, and Delaware law make it more difficult for a third party to acquire the company, potentially delaying or frustrating takeover attempts.
• Failure to build finance infrastructure and improve accounting systems and controls could impair compliance with financial reporting requirements.
• Changes in patent law could diminish the value of patents, impairing ability to protect AL001 and ALZN002.
• Inability to protect intellectual property rights throughout the world due to high costs and varying legal systems.

Future Outlook

The company intends to advance clinical development of AL001 for Alzheimer's, BD, MDD, and PTSD, and ALZN002 for Alzheimer's. It plans to expand its pharmaceutical pipeline to include additional delivery methods and indications. The strategy involves focusing on translational and functional endpoints for efficient product candidate development and optimizing the value of AL001 and ALZN002 in major markets, primarily through strategic partnerships for costly later-stage clinical development and commercialization. The company does not anticipate generating revenue for at least the next several years, if ever, or achieving profitability for several years thereafter.

Management Comments

• "We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). With our two product candidates, we aim to bring treatments or potential cures to market as quickly as possible."
• "Far too many individuals, including patients and caregivers, suffer from the burden created by these devastating, and often fatal, diseases."
• "We believe that AL001 is positioned for a Section 505(b)(2) regulatory pathway for new drug approvals. We also believe that AL001 and ALZN002 are positioned for breakthrough therapy designations because of their positive effects on a pharmacodynamic biomarker (beta-amyloids) and potential for a clinically meaningful effect on Alzheimers, making them eligible to receive assistance from the FDA throughout the approval process that may shorten the development timelines."
• "We do not anticipate selling products directly into the marketplace, though we may do so depending on market conditions. Our focus is expected to concentrate on entering into strategic transactions with established distributors and producers, which will provide distribution and marketing capabilities for the sale of our products in the marketplace."
• "We do not anticipate that we will generate our maximum revenue for several years, or that we will achieve profitability for any of our therapeutic drug candidates until at least a few years after generating material revenue, if at all."
• "This innovation is specifically designed to address the needs of fragile populations, such as elderly and Alzheimers patients, by offering a potentially more efficient and safer alternative to existing treatments."

Industry Context

The filing highlights the immense unmet medical need and significant market opportunity in Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD, with estimated healthcare costs for Alzheimer's alone reaching $384 billion in 2025 and potentially $1 trillion by 2050. The company positions its AL001 as a 'next-generation lithium treatment' aiming to overcome the narrow therapeutic window and toxicity of conventional lithium salts, which are still considered 'gold standard' for bipolar disorder. For Alzheimer's, the company's ALZN002 aims to provide active immunization, contrasting with recently approved passive immunity treatments like Leqembi (Eisai) and Kisunla (Eli Lilly), which require frequent infusions. The company acknowledges the high failure rate in Alzheimer's drug development, with only three new drugs approved since 2003, validating the amyloid theory but highlighting the challenges in finding effective treatments. Alzamend Neuro's strategy to partner with larger biopharmaceutical companies for later-stage development aligns with industry trends where smaller clinical-stage companies seek funding and commercialization expertise from established players.

Comparison to Industry Standards

• AL001 aims to be superior to existing lithium carbonate treatments by improving associative learning and memory and irritability in preclinical models, and by potentially mitigating the need for therapeutic drug monitoring (TDM) due to a wider therapeutic index.
• ALZN002's active immunization approach contrasts with recently FDA-approved passive immunization treatments for Alzheimer's, such as Lecanemab-irmb (Leqembi) from Eisai and donanemab (Kisunla) from Eli Lilly, which require bi-weekly or monthly infusions.
• The company's preclinical data for AL001 in Alzheimer's transgenic mice showed consistently higher lithium concentrations in brain tissues at lower doses compared to lithium carbonate, suggesting a potential advantage in brain bioavailability and reduced systemic side effects (e.g., thyroid and kidney complications) often associated with extant lithium therapies.
• The company's pursuit of a Section 505(b)(2) regulatory pathway for AL001 is an industry standard strategy for expedited approval of new formulations of previously approved drugs, potentially shortening development timelines compared to traditional 505(b)(1) pathways.
• The company's goal for AL001 to replace higher lithium doses for maintenance treatment of BD with a lower, clinically relevant equivalent dose aligns with efforts across the neuropsychiatric field to improve patient safety and adherence by reducing side effects and monitoring burdens.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various claims and legal actions arising in the ordinary course of business, which could be costly and distract management.
• No legal proceedings or arbitration proceedings are currently pending against the company.

Related Party Transactions

• Milton C. (Todd) Ault III, the company's Founder and Vice Chairman, has significant influence through controlling interests in Hyperscale Data, Inc. (HDI), Ault Lending, LLC, and Ault Life Sciences, Inc. (ALSI).
• William B. Horne (Chairman of the Board), Henry Nisser (Executive Vice President, General Counsel, and Director), and Kenneth S. Cragun (Senior Vice President of Finance) hold overlapping executive and director positions at the company and HDI.
• The company's accounting and finance department utilizes shared office space within HDI's offices in Costa Mesa, California, and the legal office uses shared space within HDI's offices in New York, NY, without paying rent.
• The company paid Ault Lending, a related party, an origination fee of $400,000 during the year ended April 30, 2025, related to Series A Convertible Preferred Stock purchases from Orchid Finance, LLC.
• In January 2024, the company and Ault Life Science Fund, LLC (ALSF), a related party, entered into a settlement agreement where ALSF returned 7,346 shares of Common Stock and warrants for settlement of a $14,876,293 note receivable.
• Between January 31, 2024, and April 29, 2024, the company sold 2,100 shares of Series B Convertible Preferred Stock and warrants to Ault Lending for $2.1 million, with the purchase price paid by cancellation of $1.15 million in cash advances and a $70,000 subscription receivable, plus $880,000 in cash.

Stakeholder Impact

• **Shareholders**: Face substantial dilution risk from ongoing capital raises (ATM offerings, preferred stock conversions) and potential future equity sales. The 'going concern' opinion and volatile stock price pose significant investment risks. Reverse stock splits may also impact perception and liquidity.
• **Employees**: The company's ability to attract and retain qualified personnel, including senior management and scientific staff, is critical for its future success, especially given intense competition in the biopharmaceutical field. Insufficient accounting personnel identified as a material weakness could impact internal operations.
• **Patients/Caregivers**: The company's mission to bring treatments to market for devastating diseases like Alzheimer's, BD, MDD, and PTSD offers potential future benefits. However, delays in clinical trials, particularly for ALZN002, mean longer waits for potential new therapies.
• **Creditors**: The 'going concern' opinion and recurring losses indicate increased risk for creditors, as the company's ability to meet its obligations is dependent on future financing.
• **Licensors (University of South Florida Research Foundation)**: The company's continued licensing rights are contingent on meeting operational and financial milestones, including milestone payments and royalties on future sales. Failure to meet these could result in termination of license agreements.

Next Steps

• Initiate four more Phase II imaging clinical trials for AL001: for BD (expected Q4 2025), MDD (expected Q1 2026), PTSD (expected Q1 2026), and Alzheimer's (expected Q2 2026).
• Present topline data from the AL001 Phase II imaging study in healthy human patients by the end of 2025.
• Initiate Phase III clinical trials for AL001 for respective indications upon completion of the five Phase II imaging trials.
• Seek approval to commercialize AL001 via a New Drug Application (NDA) if Phase III clinical trials are successful.
• Pursue engagement of a replacement Contract Research Organization (CRO) for the ALZN002 Phase I/IIA clinical trial.
• Resume the ALZN002 Phase I/IIA clinical trial, with resumption not expected until mid-2026.
• Seek approval to commercialize ALZN002 through a Biologics License Application (BLA) if Phase III clinical trials are successful.
• Explore different formulations (liquid, immediate release, sprinkle capsules) to deliver AL001.
• Seek breakthrough therapy designation for AL001 and ALZN002.
• Enter into strategic transactions with established distributors and producers for commercialization of AL001 and ALZN002.
• Raise substantial additional capital through public equity, private equity, and debt financings to fund future development and operations.
• Remediate identified material weaknesses in internal control over financial reporting by increasing accounting department resources and strengthening supervisory reviews.

Key Dates

Recommendation

The filing presents a highly concerning financial outlook, with the independent auditor issuing a 'going concern' opinion due to recurring losses and insufficient capital for the next 12 months. This fundamental financial instability is a critical red flag for any investor. Furthermore, a key product candidate, ALZN002, has experienced a significant and prolonged clinical trial delay, pushing potential commercialization further into the uncertain future. While AL001 shows some positive early-stage progress and the company has managed to raise capital, the sheer magnitude of the financial challenges, coupled with the operational setback in a core development program, indicates a very high-risk profile. The need for substantial future funding, the volatile stock price, and identified material weaknesses in internal controls further compound the negative sentiment. A seasoned investor would view these factors as strong indicators to exit or avoid the stock, as the probability of significant value erosion outweighs any speculative upside from early-stage drug development.

Keywords

Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder, PTSD, AL001, ALZN002, Clinical Trials, Biopharmaceutical, SEC Filing, 10-K, Drug Development, Neurodegenerative Diseases, Psychiatric Disorders, Lithium Cocrystal, Immunotherapy Vaccine, FDA Approval, Going Concern, Capital Raise, Nasdaq, Intellectual Property, Corporate Governance, Risk Factors